Maintenance Therapy and Sequencing Treatment in Multiple Myeloma
Release Date: January 16, 2019
Expiration Date: January 16, 2020
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Many patients with multiple myeloma (MM) will relapse after treatment, even after receiving standard-of-care therapy. Initiating maintenance treatment after autologous stem cell transplantation has the potential to benefit patients and may reduce risks for the development of relapsed/refractory MM. For those who relapse or become refractory to treatment, novel therapies and sequenced treatment approaches are being utilized to improve patient outcomes.
As MM treatment strategies continue to evolve, oncology nurses must remain current with recent therapeutic advances. In their efforts to optimize supportive care, nurses must ensure that patients understand the importance of maintenance therapy and be educated on why they may receive sequenced treatment and what to expect regarding efficacy and potential adverse events.
In this activity, Dr. Sarah Holstein describes the role of maintenance therapy in MM as well as efficacy and safety of emerging maintenance treatments. Dr. Paul Richardson discusses efficacy and safety data for new therapies for relapsed/refractory disease and provides strategies for making risk-adapted treatment decisions.
This activity is designed for nurses in the community setting who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize practice challenges associated with using maintenance therapies and sequenced treatment in the management of multiple myeloma (MM)
- Describe strategies for optimizing maintenance therapy in MM and efficacy and safety data associated with current and emerging maintenance treatments
- Outline efficacy and safety data for new therapies to manage relapsed/refractory MM and provide strategies for making risk-adapted treatment decisions
- Describe recent advances and future directions of maintenance therapies and sequenced treatment and their role in managing MM throughout the disease spectrum
Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient – Paul G. Richardson, MD
The Role of Maintenance Therapy for the Treatment of Multiple Myeloma – Sarah A. Holstein, MD, PhD
Instructions for Participation and Credit
This activity is eligible for credit through January 16, 2020. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.
Paul G. Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, and was chief resident at the Royal Marsden Hospital, London. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, he joined Dana-Farber Cancer Institute where he is a Professor of Medicine at the Harvard Medical School. In addition, Dr. Richardson serves as Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center and has led several novel, biologically-derived translational efforts in multiple myeloma.
Dr. Richardson is board certified in hematology, internal medicine, and medical oncology. He holds numerous advisory board positions and is a member of dozens of professional organizations. In addition, he has published hundreds of original papers, reviews, chapters, and monographs in many leading peer-reviewed publications including The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Lancet Haematology, Clinical Cancer Research, Bone Marrow Transplantation, JAMA Oncology, and the British Journal of Haematology. Dr. Richardson has led the study and clinical development of numerous novel drugs in the treatment of multiple myeloma which have contributed to improvement in outcome for patients.
Sarah A. Holstein, MD, PhD
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Dr. Sarah Holstein received her medical degree and PhD in pharmacology from the University of Iowa Carver College of Medicine. She continued her postgraduate studies there with a residency in internal medicine and a fellowship in hematology/oncology. She is currently an Associate Professor in the Division of Oncology and Hematology, Department of Internal Medicine, at the University of Nebraska Medical Center in Omaha.
Dr. Holstein holds board certification in internal medicine, hematology, oncology, as well as by the National Board of Physicians and Surgeons. She is a member of the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, American Society for Clinical Pharmacology and Therapeutics, and the International Myeloma Society of Hematologic Oncology. In addition, Dr. Holstein is a member of the Alliance Multiple Myeloma Committee and the NCCN Multiple Myeloma Panel. She has written numerous peer-reviewed research articles as well as review articles and book chapters, and is an ad hoc reviewer for dozens of peer-review journals.
As a physician-scientist who specializes in the treatment of multiple myeloma, Dr. Holstein’s laboratory is focused on gaining a better understanding of the pathophysiology and the development of novel therapeutic agents for this disease. She is an active clinical investigator, and has been involved in clinical trials for newly diagnosed myeloma, relapsed/refractory disease, as
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 19-005-095
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Paul Richardson has received honoraria related to formal advisory activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Oncopeptides, AB, and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb Company, Celgene, and Takeda Oncology.
Dr. Sarah Holstein has received honoraria as a consultant from Celgene Corporation.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.